Thyroid Carcinoma Panel Sequencing

Thyroid Carcinoma Panel Sequencing

Description of Papillary Thyroid Carcinoma

Papillary thyroid carcinoma (PTC) is the most common cancer of the endocrine system and accounts for most thyroid cancer cases in the past decades. PTC is usually indolent and curable and has a 5-year survival rate >95%. However, in some cases, PTC will de-differentiate and become aggressive, resulting in a poor prognosis. Previous reports have revealed that genetic alterations, such as BRAF mutations, TERT mutations, can promote tumor proliferation and metastasis, which result in poor PTC prognosis; these actions are mediated through the Mitogen-Activated Protein Kinase (MAPK/ERK) and Phosphoinositide 3-kinase (PI3K) / Protein kinase B (AKT) pathways. However, the pathogenesis of PTC has not yet been fully elucidated.

To support clinical researches, CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low frequency variations in thyroid carcinoma-associated genes. If necessary, you can choose genes that fit your requirements.

Gene List of Thyroid Carcinoma Panel

AKT1 BRAF CDKN2A CTNNB1 EGFR HRAS hTERT KRAS NOTCH1 NRAS
PIK3CA PTEN TP53 TSHR            

Highlights of Thyroid Carcinoma Panel Sequencing Service

  • Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with lower costs.
  • High coverage uniformity ensures the sequencing data more efficiency.
  • SNVs, indels, and even low frequency variations can be detected.
  • Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
  • Fast turnaround time.

Applications of Thyroid Carcinoma Panel Sequencing

  • Cancer related mechanism studies
  • Biomarker discovery
  • Therapeutic target discovery
  • Drug target discovery
  • Discover rare mutations and detect low frequency mutations

Service Specifications

Service Specifications

Sample Requirements

  • Sample types for genome DNA from tissues, whole blood, cultured cells, and formalin-fixed paraffin-embedded (FFPE) tissues.
  • Recommended amount: 2μg
  • Minimum amount: 200ng
  • Collection: DNA samples are stored in TE buffer or equivalent. Blood is collected by routine blood collection kits.
Service Specifications

Sequencing

  • Illumina PE150
  • Enrichment Method: Amplicon sequencing
  • More than 80% of bases with a ≥Q30 quality score
  • Recommended sequencing depth: ≥ 500x
Service Specifications

Bioinformatics Analysis

We provide customized bioinformatics analysis including:

  • Read alignment
  • Variant calling/Annotation

Gene Panel Workflow

CD Genomics provides the accurate and cost-effective thyroid carcinoma panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for thyroid carcinoma panel sequencing is outlined below.

Gene Panel Workflow

Clinical Guidance on Gene Mutation by NCCN Guideline

Gene Targeted Drugs
BRAF Dabrafenib, Trametinib

For more information about the thyroid carcinoma panel or need other amplification requirements, please contact us.

References:

  1. La V C, et al. Thyroid cancer mortality and incidence: a global overview. Int. J. Cancer, 2015. 136, 2187–2195.
  2. Siegel R L, et al. Cancer statistics. Ca. Cancer J. Clin, 2016. 66, 7–30.
  3. Xing M, et al. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer, 2013. 13, 184–199.
* For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry
  • Please input "genomics" as verification code.

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-275-3058 (USA)
           44-208-144-6005 (Europe)
  • 1-631-614-7828
  • info@cd-genomics.com
Copyright © 2009 - 2020 CD Genomics. All rights reserved.
0
Inquiry Basket